Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of BG2109 in Heavy Menstrual Bleeding Associated With Uterine Fibroids
NCT05620355Phase 3Unknown
- Sponsor
- Genuine Biotech
- Start
- Dec 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of linzagolix in Uterine Fibroids (UF), sponsored by Genuine Biotech. Status: unknown.
02
Drugs
linzagolix
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT05620355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620355.